^
    3ms
    Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma (clinicaltrials.gov)
    P2, N=52, Active, not recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Jun 2025 --> Dec 2025
    Trial completion date
    |
    Photofrin (porfimer sodium)
    7ms
    Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, Roswell Park Cancer Institute | Trial completion date: Oct 2025 --> Oct 2026
    Trial completion date
    |
    Photofrin (porfimer sodium)
    8ms
    Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer (clinicaltrials.gov)
    P1/2, N=19, Terminated, Roswell Park Cancer Institute | Trial completion date: Feb 2030 --> Jul 2024 | Active, not recruiting --> Terminated; was paused by device company for a long period of time
    Trial completion date • Trial termination
    |
    Photofrin (porfimer sodium)
    11ms
    Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer (clinicaltrials.gov)
    P1, N=5, Terminated, Roswell Park Cancer Institute | Trial completion date: Nov 2023 --> Oct 2024 | Trial primary completion date: Nov 2023 --> Oct 2024
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Photofrin (porfimer sodium)
    12ms
    Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma (clinicaltrials.gov)
    P2, N=52, Active, not recruiting, Abramson Cancer Center at Penn Medicine | Recruiting --> Active, not recruiting | N=102 --> 52
    Enrollment closed • Enrollment change
    |
    Photofrin (porfimer sodium)
    1year
    Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer (clinicaltrials.gov)
    P1/2, N=19, Active, not recruiting, Roswell Park Cancer Institute | Trial primary completion date: Nov 2023 --> Jul 2024
    Trial primary completion date • Endobronchial ultrasound • Metastases
    |
    Photofrin (porfimer sodium)
    1year
    Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer (clinicaltrials.gov)
    P1, N=5, Terminated, Roswell Park Cancer Institute | Active, not recruiting --> Terminated; Low accrual
    Trial termination • Metastases
    |
    Opdivo (nivolumab) • Photofrin (porfimer sodium)
    1year
    Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer (clinicaltrials.gov)
    P1, N=5, Active, not recruiting, Roswell Park Cancer Institute | Recruiting --> Active, not recruiting | N=12 --> 5
    Enrollment closed • Enrollment change • Metastases
    |
    Opdivo (nivolumab) • Photofrin (porfimer sodium)
    1year
    Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease (clinicaltrials.gov)
    P1, N=5, Active, not recruiting, Roswell Park Cancer Institute | Suspended --> Active, not recruiting | N=16 --> 5 | Trial completion date: Mar 2025 --> Jan 2026 | Trial primary completion date: Mar 2025 --> Feb 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Photofrin (porfimer sodium)
    over1year
    Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma (clinicaltrials.gov)
    P2, N=102, Recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: May 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    Photofrin (porfimer sodium)
    over1year
    Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer (clinicaltrials.gov)
    P1/2, N=19, Active, not recruiting, Roswell Park Cancer Institute | Recruiting --> Active, not recruiting | N=65 --> 19 | Trial primary completion date: Feb 2030 --> Nov 2023
    Enrollment closed • Enrollment change • Trial primary completion date • Endobronchial ultrasound • Metastases
    |
    Photofrin (porfimer sodium)
    over1year
    Comprehensive analysis of hub genes associated with cisplatin-resistance in ovarian cancer and screening of therapeutic drugs through bioinformatics and experimental validation. (PubMed, J Ovarian Res)
    This study reveals changes in the expression level of some genes associated with cisplatin-resistant ovarian cancer. In addition, a new small molecule compound was identified for the treatment of cisplatin-resistant ovarian cancer.
    Journal
    |
    B2M (Beta-2-microglobulin) • ERBB4 (erb-b2 receptor tyrosine kinase 4) • NDRG1 (N-Myc Downstream Regulated 1) • SLIT2 (Slit Guidance Ligand 2) • ANK3 (Ankyrin 3)
    |
    cisplatin • Photofrin (porfimer sodium)